期刊文献+

5-ALA荧光膀胱镜的应用对非肌层浸润性膀胱癌早期复发率的影响 被引量:2

Influence of Using 5-aminolevulinic Acid Induced Fluorescence Cystoscopy on Early Recurrence Rate in Non Muscle-invasive Bladder Cancer
原文传递
导出
摘要 目的:探讨5-氨基乙酰丙酸(5-ALA)荧光膀胱镜的应用对非肌层浸润性膀胱癌术后早期复发率的影响。方法:将90例非肌层浸润性膀胱癌患者随机分为两组,每组45例,分别在白光膀胱镜和5-ALA荧光膀胱镜下行TURBt,术后6周所有患者均行5-ALA荧光膀胱镜检查以观察肿瘤复发情况,并对复发肿瘤行二次TURBt。结果:行二次TURBt后,90例患者中,25例(27.7%)发现有肿瘤发生,其中白光膀胱镜组18例(40%),荧光膀胱镜组7例(15.5%),两组间比较差异有统计学意义(P=0.05)。结论:5-ALA荧光膀胱镜对膀胱肿瘤的诊断和治疗具有较高价值,可以显著降低非肌层浸润性膀胱癌术后早期复发率。 Objective:To evaluate the value of using 5-aminolevulinic acid induced fluorescence cystoscopy on early recurrence rate in non muscle-invasive bladder cancer. Methods: In a prospective randomized study 90 patients underwent transurethral resection of bladder tumor(s) either with white light or ALA fluorescence assisted cysto- scopy. A second look transurethral resection with ALA fluorescence cystoscopy was performed 6 weeks after the initial operation. Results: At second look transurethral resection tumor was detected in 18 of 45 patients(40%) in the white light cystoscopy group and in 7 of 45 (15.6%) in the ALA fluorescence cystoscopy group. This differ- ence was statistically significant(P = 0.05). Conclusions: 5-ALA induced fluorescence cystoscopy is an effective and valuable detection and treatment method which can significantly reduce early recurrence rate in non muscle-invasive bladder cancer.
出处 《临床泌尿外科杂志》 北大核心 2011年第6期422-424,共3页 Journal of Clinical Urology
关键词 膀胱肿瘤 荧光膀胱镜 bladder neoplosms fluorescence cystoscopy
  • 相关文献

参考文献15

  • 1Sylvester R J, Van der Meijden P M, Oosterlinck W, et al. Predicting recurrence and progression in individual patientswith stages Ta Tlbladder cancer using EORTC risk tables., a combined analysis of 2596 patients from seven EORTC Trials [J].Eur Urol, 2006, 49(3): 466--477.
  • 2Joudi F N, Konety B R. Fluorescence cystoscopy and bladder surveillance[J].Curr Opin Urol, 2004, 14:265-270.
  • 3Van Rhijn B W G, Burger M, Lotan Y, etal. Recurrence and progression of disease in non-muscle-invasive bladder cancer; From epidemiology to treatment strategy[J]. Eur Urol, 2009, 56 (3): 430-442.
  • 4Zaak D, Karl A, Knuchul R, et al. Diagnosis of urothelial carcinoma of the bladder using fluorescence endoscopy[J]. BJU Int, 2005, 96: 217-222.
  • 5Schwaibold H E, Treiber U, Kuebler H, etal. Second transurethral resection detects histopathological changes worsening the prognosis in 25% of patients with pT1 bladder cancer[J]. J Urol, 2000, 163: 153- 154.
  • 6Zurkirchen M A, Sulser T, Gaspert A, etal. Second transurethral resection of superficial transitional cell carcinoma of the bladder:a must even for experienced urologists[J]. Urol Int, 2004, 72 : 99-102.
  • 7Schwaibold H E, Treiber U, Kubler H, et al. Significance of 2 nd transurethral resection for T1 bladder cancer[J].Eur Urol, 2000, 37(Suppl): 111.
  • 8Engelhardt P F, Riedl C R, Pfluger H. Is a second look TUR in patients with superficial bladder cancer necessary[J].? J Endourol, 1998,12(Suppl) : S128.
  • 9Jeon S S, Kang I, Hong J H, et al. Diagnostic efficacy of fluorescence cystoscopy for detection of urothelial neoplasms[J]. J Endourol, 2001,15 (7) : 753--759.
  • 10De Dominicis C, Liberti M, Perugia GI etal. Role of 5-aminolevulinic acid in the diagnosis and treatment of superficial bladder cancer: improvement in diagnostic sensitivity[J]. Urology, 2001, 57(6):1059-1062.

同被引文献15

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部